Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging

Sirtris Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that findings in the journal Nature demonstrate that Sirtris has developed novel drug candidates that offer a promising, new approach to treating diseases of aging, including Type 2 Diabetes, by targeting SIRT1, a gene that controls the aging process.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news115478536.html">Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging</a></p> <p>Sirtris Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that findings in the journal Nature demonstrate that Sirtris has developed novel drug candidates that offer a promising, new approach to treating diseases of aging, including Type 2 Diabetes, by targeting SIRT1, a gene that controls the aging process.</p>